Sector News

ConvaTec owners appoint banks to explore sale – sources

October 15, 2014
Chemical Value Chain
(Reuters) – ConvaTec’s owners have appointed Morgan Stanley and Goldman Sachs to explore a sale of the medical device maker which could be worth up to $10 billion, sources familiar with the matter said.
 
Private equity firms Avista Capital Partners and Nordic Capital are preparing the groundwork for a possible sale or initial public offering (IPO) in 2015 for the Luxembourg-based company, said the sources who spoke on condition of anonymity because the process is private.
 
Mergers and acquisitions in the healthcare space have hit a record pace so far this year, in part driven by U.S. companies seeking to redomicile in countries that have a lower corporate tax rate, in a practice known as inversion.
 
Kimberley-Clark and 3M are considered likely bidders for ConvaTec, said the sources, adding that the U.S. firms’ interest was not motivated by tax inversion issues.
 
ConvaTec, Nordic Capital, 3M, Goldman Sachs and Morgan Stanley declined to comment. Kimberley Clark and Avista Capital did not immediately respond to requests for comment.
 
Reuters reported in August that some U.S. companies including diversified manufacturer 3M and medical equipment makers CareFusion Corp and C.R. Bard Inc were potentially exploring a deal, but that ConvaTec wanted to boost its value further before launching an auction or IPO.
 
CareFusion has since been swallowed by medical equipment supplier Becton Dickinson & Co for $12.2 billion, taking them out of the field.
 
Also, in recent weeks equity markets have stumbled and the market for IPOs has stalled.
 
Avista Capital Partners and Nordic Capital acquired ConvaTec from Bristol-Myers Squibb Co in 2011 for $4.1 billion. 3M and Kimberley-Clark were among the contenders for ConvaTec at the time, according to people familiar with the matter.
 
ConvaTec reported earnings before interest, tax, depreciation and amortization (EBITDA) of $502.5 million in 2013, up 15 percent year-on-year. It is hoping to exceed $600 million in EBITDA this year, sources have said.
 
The company makes wound care and ostomy care products at 11 manufacturing sites in eight countries, and sells them in more than 100 countries.
 
BY SOPHIE SASSARD AND ANJULI DAVIES (Editing by Pravin Char)

comments closed

Related News

January 29, 2023

Dow and 3M cut thousands of jobs

Chemical Value Chain

3M and Dow have announced they are cutting thousands of roles from their global workforces in response to economic pressures. Dow has said it will cut 2,000 jobs across its global workforce (around 5%) in a bid to save US$1bn in 2023. The company says it will also cut costs by shutting down “select assets”, though it did not note where it would halt operations.

January 29, 2023

Sweden discovers Europe’s largest rare earths deposit

Chemical Value Chain

Sweden’s state mining firm has discovered what could be Europe’s largest rare earths deposit, and says it could help the bloc reduce its reliance on imports of minerals needed to manufacture clean technologies and meet climate targets.

January 29, 2023

Avantium to supply Henkel with plant-based FDCA

Chemical Value Chain

Henkel and Avantium have been partners since 2019, when Henkel joined the PEFerence consortium. This consortium of partners, coordinated by Avantium, aims to establish an innovative supply chain for FDCA and PEF (polyethylene furanoate).

How can we help you?

We're easy to reach